Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07413926 · ClinicalTrials.gov registry record
Mitral Valve Repair With the Chord-X System: A Long Term Evaluation
A clinical trial, sponsored by Artivion.
- Not yet
- Registry status
- 110
- Enrollment target
NCT07413926: Clinical Trial study, sponsored by Artivion.
NCT07413926 is a clinical trial that has not yet begun recruiting, run by Artivion. The registered enrollment target is 110 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07413926 has not yet begun recruiting, sponsored by Artivion.
- NOT YET RECRUITING
- Registry status
- 110 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to strengthen the evidence available for the Chord-X System by collecting follow-up data from patients who underwent Chord-X implant and to evaluate the long-term safety and performance data (out to 10 years). Collecting patient health information over time can help to supplement and improve the care of patients in the future. Participants will: Agree to the collection of their past medical history, and the details of their mitral repair surgery with the Chord-X system, including results of the follow-up examinations after implantation Visit the clinic for the routinely scheduled follow-up examination appointments
Primary Outcome
The primary endpoint of the study is recurrent moderate to severe (3+) mitral regurgitation (MR). Mitral regurgitation severity is classified as none/trivial (0), mild (1+), moderate (2+), moderate to severe (3+) or severe (4+). The wording moderate to severe is used to describe the upper end of the moderate range. The process of grading MR is comprehensive, using a combination of clues, signs and measurements obtained by Doppler echocardiography.
Interventions
- DEVICE Chord-X system implant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2026-06 |
| Est. Completion | 2034-06 |
What is known before NCT07413926 opens enrollment
NCT07413926 is an observational study that tracks outcomes without assigning an intervention. The registered 110 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Chord-X system implant is the first listed.
NCT07413926 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07413926 about?
NCT07413926 is a clinical study titled "Mitral Valve Repair With the Chord-X System: A Long Term Evaluation". The goal of this clinical trial is to strengthen the evidence available for the Chord-X System by collecting follow-up data from patients who underwent Chord-X implant and to evaluate the long-term safety and performance data (out to 10 years). Collecting patient health information over time can hel...
What is the current status of trial NCT07413926?
This trial is currently not yet recruiting. The enrollment target is 110 participants. The study started on 2026-06. Estimated completion is 2034-06.
What interventions are being tested in trial NCT07413926?
The interventions under investigation include: Chord-X system implant (DEVICE).
Who is sponsoring clinical trial NCT07413926?
This trial is sponsored by Artivion, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01530373 · 110 participants · Phase 2
Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients
- NCT02379377 · 110 participants · Phase 1
18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant
- NCT02411773 · 110 participants · Phase 1
Sympatholysis in Chronic Kidney Disease
- NCT03190941 · 110 participants · Phase 1
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia